Synonyms: compound of formula A [US20220024908A1] | TGRX-326 | TGRX326
Compound class:
Synthetic organic
Comment: The chemical structure for deulorlatinib was obtained from WHO proposed INN list 131 (August 2024). Chemically it is a deuterated analogue of the approved dual ALK/ROS1 inhibitor lorlatinib. Deulorlatinib is claimed in Shenzen Targetrx patent US20220024908A1 [1], and we predict that deulorlatinib is the INN for their lead compound TGRX-326 (based on their disclosed pipeline and a meeting abstract [2]).
|
|
References |
1. Wang Y, Li H. (2022)
Preparation method for deuterated macrocyclic compound. Patent number: US20220024908A1. Assignee: Shenzhen Targetrx. Priority date: 27/11/2019. Publication date: 27/01/2022. |
2. Zhao H, Ma Y, Yang N, Wang Z, Jin W, Li W, Liu Y, Meng R, Zhou J, Cheng Y et al.. (2023)
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer. Journal of Clinical Oncology, 41 (16 Supplement). DOI: 10.1200/JCO.2023.41.16_suppl.9113 |